Daiichi Sankyo Company (4568) Q3 2026 earnings summary

Executive summary

• Revenue grew 12.1% year-over-year to JPY 1,533.5 billion, driven by strong oncology product sales, especially ENHERTU and DATROWAY, despite negative FX impacts.

• Core operating profit rose 8.8% year-over-year to JPY 249.2 billion, while operating profit declined 5.9% due to absence of prior year’s one-time gains and higher temporary expenses.

• Profit attributable to owners increased 4.2% year-over-year to JPY 217.4 billion, aided by lower income taxes.

• No changes to full-year consolidated earnings forecast since October; product-level sales forecasts updated.

• Total comprehensive income rose 11.7% to JPY 267.3 billion, supported by favorable currency translation differences.

Financial highlights

• Revenue up JPY 165.9 billion year-over-year, with cost of sales, SG&A, and R&D expenses also increasing.

• Core operating profit increased by JPY 20.2 billion; operating profit decreased by JPY 14.5 billion due to lack of temporary income from prior year and higher temporary expenses.

• Financial income and expenses contributed positively by JPY 9.5 billion.

• Income taxes decreased by JPY 13.9 billion, reflecting lower pre-tax income and effective tax rate.

• Basic EPS for the period was JPY 117.34, up from JPY 109.65 year-over-year.

Outlook and guidance

• No change to FY2025 consolidated earnings forecast from October announcement.

• Full-year DATROWAY sales forecast raised by JPY 9.2 billion to JPY 47 billion due to higher-than-expected demand.

• Full-year revenue forecast is JPY 2,100.0 billion (+11.3%), with core operating profit of JPY 350.0 billion (+11.9%).

• Profit attributable to owners is projected at JPY 288.0 billion (-2.6%), with basic EPS of JPY 155.59.

• Upcoming regulatory decisions and key data readouts expected in the next fiscal year for major oncology trials.